BIO

Bio-Rad Laboratories, Inc.Class A New York Stock Exchange
$625.74
Open: $626 High: $627.32 Low: $616.9 Close: $625.33
Range: 2021-06-19 - 2021-06-21
Volume: 26,267
Market: Open
Powered by Finage Stock APIDelayed data
BIO
Bio-Rad Laboratories, Inc.Class A 1000 Alfred Nobel Drive Hercules CA, 94547 http://www.bio-rad.com
Bio-Rad Laboratories Inc manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a products and systems used to separate complex chemical and biological materials.
  • CEO: Norman Schwartz
  • Employees: 8,150
  • Sector: Healthcare
  • Industry: Medical Diagnostics & Research
BIO News
Latest news about the BIO
  • Hedge Funds Are Nibbling On Bio-Rad Laboratories, Inc. (BIO)

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 866 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

    View More →
  • Bio-Rad Launches Its PREvalence ddPCR SARS-CoV-2 Wastewater Quantification Kit for COVID-19 Wastewater Testing

    HERCULES, Calif., Jun 21, 2021--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of its PREvalence™ ddPCR® SARS-CoV-2 Wastewater Quantification Kit, a sensitive, accurate, and cost-effective tool used to detect SARS-CoV-2 in a community’s wastewater.

    View More →
  • Top Healthcare Stocks for June 2021

    These are the healthcare stocks with the best value, fastest growth, and most momentum for June 2021.

    View More →
  • Bio-Rad to Participate at Jefferies Virtual Healthcare Conference

    Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO; Andrew Last, Executive Vice President and COO; and Ilan Daskal, Executive Vice President and CFO, will participate in a Fireside Chat at Jefferies Virtual Healthcare Conference on Wednesday, June 2, at noon (Pacific Time).

    View More →
  • Was The Smart Money Right About Bio-Rad Laboratories, Inc. (BIO)?

    Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 900 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]

    View More →
  • Why I Relish Low-Debt Stocks

    When it comes to picking stocks, most investors go gaga over earnings and pay little attention to a company's financial strength

    View More →
  • Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Guidance Up

    Bio-Rad's (BIO) first-quarter revenues improved year over year on robust growth in Life Science and Clinical Diagnostics segments.

    View More →
  • Bio-Rad Laboratories Inc (BIO) Q1 2021 Earnings Call Transcript

    With me on the phone today are Norman Schwartz, our Chief Executive Officer; Ilan Daskal, Executive Vice President and Chief Financial Officer; Andy Last, Executive Vice President and Chief Operating Officer; Annette Tumolo, President of the Life Science Group; and Dara Wright, President of the Clinical Diagnostics Group. Before we begin our review, I would like to caution everyone that we will be making forward-looking statements about management's goals, plans and expectations, our future financial performance and other matters.

    View More →
  • Is It Too Late To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?

    Let's talk about the popular Bio-Rad Laboratories, Inc. ( NYSE:BIO ). The company's shares saw a decent share price...

    View More →
  • Bio-Rad Laboratories (BIO) Q1 Earnings and Revenues Beat Estimates

    Bio-Rad (BIO) delivered earnings and revenue surprises of 108.40% and 9.95%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

    View More →
  • Bio-Rad Reports First-Quarter 2021 Financial Results

    Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2021.

    View More →
  • What Investors Need to Know About 10x Genomics

    In this episode of Industry Focus: Wildcard, Motley Fool Analyst Maria Gallagher joins host Emily Flippen to discuss the prospects for 10x Genomics (NASDAQ: TXG), a healthcare tech company looking to reform the way researchers discover single-cell gene expression. To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. Today, I am joined by Motley Fool Analyst Maria Gallagher, as we wade back into the healthcare waters and talk about an interesting play on healthcare tech and consumables, 10x Genomics.

    View More →
  • BioRad (BIO) to Report Q1 Earnings: What's in the Cards?

    Growing demand for Polymerase Chain Reaction and Droplet Digital PCR products is expected to have contributed to BioRad's (BIO) Q1 growth.

    View More →
  • Bio-Rad Laboratories (BIO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

    Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    View More →
  • Bio-Rad to Report First-Quarter 2021 Financial Results, Thursday, April 29, 2021

    Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the first quarter 2021 on Thursday, April 29, 2021, following the close of the market. The company will discuss these results in a conference call scheduled for 3 PM Pacific Time (6 PM Eastern Time) that day.

    View More →
  • Thermo Fisher (TMO) Rides on End Markets as Pandemic Rages On

    In diagnostics and healthcare, Thermo Fisher (TMO) is experiencing high demand for COVID-19 testing and manages to record 200% growth.

    View More →
  • Logitech, Harley-Davidson, Fulgent Genetics, Bio-Rad Laboratories and IDEXX Laboratories highlighted as Zacks Bull and Bear of the Day

    Logitech, Harley-Davidson, Fulgent Genetics, Bio-Rad Laboratories and IDEXX Laboratories highlighted as Zacks Bull and Bear of the Day

    View More →
  • COVID-19 Resurgence Accelerates Diagnostic Testing: 3 Top Picks

    We have narrowed down our search to the following stocks, FLGT, BIO and IDXX based on a favorable Zacks Rank and strong prospects for 2021.

    View More →
  • Is Bio-Rad (BIO) Stock A Buy or Sell?

    Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow nearly 900 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]

    View More →
  • Analysts See Plenty of Potential for 10x Genomics

    The biotech's stock has tripled since going public, but it faces some stiff challenges

    View More →